[1] PIROZYNSKI M.100 years of lung cancer[J].Respir Med,2006,100(12):2073-2084.
[2] IRMLER M,THOME M,HAHNC M,et al.Inhibition of death receptor signals by cellular FLIP[J].Nature,1997,388:190-195.
[3] SHIMADA K,NAKAMURA M,MATSUYOSHI S,et al.Specific positive and negative effects of FLIP on cell survival in human prostate cancer[J].Carcinogenesis,2006,27:1349-1357.
[4] ZHANG J,CHEN Y Z,HUANG Q L,et al.Nuclear localization of c-FLIP(L)-L and its regulation of AP-1 activity[J].Int J Biochem Cell Biol,2009,41(8):1678-1684.
[5] SAFA A R.c-FLIP(L),a master anti-apoptotic regulator[J].Exp Oncol,2012,34(3):176-184.
[6] AHMAD R,SAFA A R,TRAVIS W D,et al.Cellular FLICE-like inhibitory protein(C-FLIP(L)):a novel target for cancer therapy[J].Current Cancer Drug Targets,2008,8:37-46.
[7] 黄晓琳,曹子昂,潘文标,等.肺癌组织中wip1的表达及其临床意义[J].现代医学,2013,41(9):629-634.
[8] FIFE C M,MCCARROLL J A,KAVALLARIS M.Movers and shakers:cell cytoskeleton in cancer metastasis[J].Br J Pharmacol,2014,171(24):5507-5523.
[9] KATAOKA T,BUDD R C,HOLLER N,et al.The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways[J].Curr Biol,2000,10:640-648.
[10] GOLKS A,BRENNER D,KRAMMER P H,et al.The c-FLIP(L)-NH2 terminus(p22-FLIP)induces NF-κB activation[J].J Exp Med,2006,203:1295-1305. |